Focused On-demand Library for Glucokinase regulatory protein

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q14397

UPID:
GCKR_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q14397; A1L4C2; B4DPQ2; Q53RY6; Q99522

BACKGROUND:
Glucokinase regulatory protein, by interacting with glucokinase, serves as a crucial regulator of glucose homeostasis. It adjusts glucokinase's affinity and activity through its interaction with fructose metabolites, playing a significant role in the postprandial (after meal) regulation of glucose levels. This protein's ability to shuttle glucokinase between the nucleus and cytoplasm underscores its importance in metabolic processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Glucokinase regulatory protein unveils potential avenues for therapeutic intervention. Given its significant influence on glucose regulation, targeting this protein could lead to breakthroughs in treating metabolic diseases, marking a step forward in medical research and drug development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.